state of Vivus

Discussion in 'Vivus Pharmaceuticals' started by Anonymous, Sep 4, 2013 at 8:11 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    3 CEOs in 1 year.
    Generic phentermine and topiramate ER.
    Managed care coverage slim to none.
    Minimal to zero communication to field.
    IMS data manipulated before dispersed, thus delays.
    "Home made bread" condoned by management.
     

  2. Anonymous

    Anonymous Guest

    What homemade bread? What are you talking about?
     
  3. Anonymous

    Anonymous Guest

    context here
    first CEO was in place 20 years, 2nd had a medcial issue, 3rd is new - so 3 in a year is true but...
    managed care is better than Belviq
    I actually like not getting bombarded with messages/emails/etc
    I think the Rx data at this place has the best I have ever worked with - not projected
    have no idea what the last comment means
     
  4. Anonymous

    Anonymous Guest

    ceo - medical issue, media spin probably wanted to disassociate

    3rd ceo - usually interim ceo placed until suitable one found in a few months....this one had one foot in the door

    generic phentermine, generic topiramate ER AND branded topiramate ER both available

    Context: 3 CEOs in 2 months.....
     
  5. Anonymous

    Anonymous Guest

    Being asked to bundle promotional materials in plastic bags or sheet protectors by west region mgr. Asked to make call notes in a three ring binder.
     
  6. Anonymous

    Anonymous Guest

    The state of Vivis is dead without a partnership with a big pharma company. Your management totally f....ked up the launch of this product. A contract sales force hired to sell with all the big promises of ground floor opportunity, chance to be a part of something special, we don't want to be like all the other pharma companies is all total bullshit. All of the managers and most of the reps were kicked to the curb by another pharma company is a downsizing move and this ship is taking on water fast as well, watch and see.
     
  7. Anonymous

    Anonymous Guest

    Approved with a REMS like no other product (ever) and only available in four pharmacies - mail order. Thank the FDA - not Vivus. Do not be a dope - this was perfectly played by the FDA - they did not want a big launch of an obesity drug.

    And get over yourself on the contract sales force bit. Vivus could not hire a sales force - the sales force outnumber the entire employee base in the home office. This is small pharma reality - shop around. This is high risk and high reward. The fact is this product needs a bigger sales force then Vivus can afford.

    BTW this contract sales force still outsells Belviq 3X.

    Go back to big pharma - oh wait a minute - they kicked you out.
     
  8. Anonymous

    Anonymous Guest

    Just like you
     
  9. Anonymous

    Anonymous Guest

    First Half Financial Results

    Net product revenue from sales of Qsymia in the first half of 2013 was $9.6 million. For the six months ended June 30, 2013, we reported a net loss of $109.1 million, or $1.08 net loss per share, as compared to a net loss of $42.8 million, or $0.45 net loss per share during the first half of 2012. The increased net loss in the first half of 2013 is again primarily attributable to increased selling, general and administrative expenses related to commercialization activities for Qsymia. Included in the net loss for the six months ended June 30, 2013 were $3.5 million related to the proxy contest and a total charge of $10.2 million for Qsymia inventories, including a purchase commitment fee, as explained above.
     
  10. Anonymous

    Anonymous Guest

    Contractual Obligations

    On May 22, 2012, we entered into a Dedicated Sales Team Agreement with PDI, Inc., as amended to date, or the Sales Team Agreement, to provide us with promotional and commercialization support services for Qsymia. The Sales Team Agreement is effective beginning on August 20, 2012 and ending on August 19, 2014. We have the option to extend the term of the agreement for two consecutive twelve-month periods. Under the terms of the Sales Team Agreement, PDI will provide us with 150 full-time sales representatives, three full-time field liaison managers, and one full-time account manager. In addition, under the Sales Team Agreement, PDI will provide us with program personnel to collect and capture physician information, including physician target call plan reach and frequency, deactivation information related to physician accounts and physician’s behavioral or attitudinal response. Our total obligation under the Sales Team Agreement is $59.6 million, including the start-up, deployments fees and compensation costs.
     
  11. Anonymous

    Anonymous Guest

    In other VIVUS news, CFO Timothy E. Morris sold 10,654 shares of the company’s stock on the open market in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $11.95, for a total value of $127,315.30. The transaction was disclosed in a filing with the SEC, which is available at this link."
     
  12. Anonymous

    Anonymous Guest

    Hear PDI is hiring for VIvus. Any feedback on territories and DMs? Greatly appreciate any news. Have heard a lot of negative.
     
  13. Anonymous

    Anonymous Guest

    Product good
    Vivus bad
    PDI bad
    DMs very bad
    Environment toxic
    Reps treated poorly
    Bonus , yea right
     
  14. Anonymous

    Anonymous Guest

    Southern California DM good New York DM decent. Heard others were train wrecks with high turnover and HR issues
     
  15. Anonymous

    Anonymous Guest

    HR issues, lack of business ethics, etc., and by the way, should anyone decide to provide the courtesy 2 weeks notice prior to resigning, don't. They will become vindictive, and terminate you immediately. (In conjunction with PDI). FYI.
     
  16. Anonymous

    Anonymous Guest

    It sounds like you are a PDI / Vivus Rep that resigned recently. Good luck, and I hope that you are going to a better position. Based on my experience, most pharmaceutical companies to not want two-weeks notice. They assume that you will not be much of an assett over that two-week period so they just accept your resignation immediately. To my knowledge, that is the industry standard.
     
  17. Anonymous

    Anonymous Guest

    Personal call notes and diaries prohibited in pharma. Don't do it.
     
  18. Anonymous

    Anonymous Guest

    Agree. For years, call notes, pre and post have been eliminated by pharma due to legalities and severe consequences involved. That is why there is no opportunity to input into the "all knowing ipads," yet management insists that reps use the pen and paper form for notes? Really? Don't do it. Setting yourselves up, or rather management is setting you up.
     
  19. Anonymous

    Anonymous Guest

    Vivus Inc. president to quit Oct. 12
    Peter Tam will quit his job as president at drug company Vivus Inc. on Oct. 12. Tam has worked at the Mountain View company (NASDAQ: VVUS) for two decades. Vivus seeks to treat obesity, sleep apnea …
     
  20. Anonymous

    Anonymous Guest

    I love getting my company news from Seeking Alpha. God forbid we ever hear anything from Vivus. Could it be any clearer they don't value the sales force at all?